SB
FULC icon

Samsara BioCapital’s Fulcrum Therapeutics FULC Stock Holding History

Samsara BioCapital’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-294,118
Closed -$3.44K – 46
2020
Q4 		$3.44K Hold
294,118
– – 0.35% 27
2020
Q3 		$2.33M Hold
294,118
– – 0.65% 26
2020
Q2 		$5.38M Buy
+294,118
New +$4.63M 1.73% 15

Other funds holding FULC

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital's FULC Position: Q1 2021 in Review

Samsara BioCapital sold out of Fulcrum Therapeutics (FULC) in Q1 2021, closing a stake of 294,118 shares — an estimated $3.44K sold.

Samsara BioCapital first reported a position in FULC in Q2 2020 and held it in 3 quarters. The position peaked at $5.38M in Q2 2020. 68 funds tracked by Wall St. Rank hold FULC as of Q1 2021.

  • Samsara BioCapital reported no remaining Fulcrum Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Samsara BioCapital sold 294,118 Fulcrum Therapeutics shares in Q1 2021, an estimated $3.44K.
  • Samsara BioCapital first reported a position in Fulcrum Therapeutics in Q2 2020 and held it in 3 quarters.
  • Samsara BioCapital's Fulcrum Therapeutics position peaked at $5.38M in Q2 2020.
  • 68 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2021.

Based on Samsara BioCapital's 13F filing for Q1 2021, filed 18 May 2021.